286 related articles for article (PubMed ID: 30072066)
1. Grade II and III Oligodendroglioma and Astrocytoma.
van den Bent MJ; Chang SM
Neurol Clin; 2018 Aug; 36(3):467-484. PubMed ID: 30072066
[TBL] [Abstract][Full Text] [Related]
2. Diffuse Infiltrating Oligodendroglioma and Astrocytoma.
van den Bent MJ; Smits M; Kros JM; Chang SM
J Clin Oncol; 2017 Jul; 35(21):2394-2401. PubMed ID: 28640702
[TBL] [Abstract][Full Text] [Related]
3. Current Considerations in the Treatment of Grade 3 Gliomas.
Jo J; Schiff D
Curr Treat Options Oncol; 2022 Sep; 23(9):1219-1232. PubMed ID: 35913658
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of molecular analysis in diffuse glioma stratification.
Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Fujioka Y; Takigawa K; Funakoshi Y; Suzuki SO; Iwaki T
Brain Tumor Pathol; 2021 Jul; 38(3):210-217. PubMed ID: 34268651
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.
Tabouret E; Nguyen AT; Dehais C; Carpentier C; Ducray F; Idbaih A; Mokhtari K; Jouvet A; Uro-Coste E; Colin C; Chinot O; Loiseau H; Moyal E; Maurage CA; Polivka M; Lechapt-Zalcman E; Desenclos C; Meyronet D; Delattre JY; Figarella-Branger D;
Acta Neuropathol; 2016 Oct; 132(4):625-34. PubMed ID: 27573687
[TBL] [Abstract][Full Text] [Related]
6. Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in
Batchala PP; Muttikkal TJE; Donahue JH; Patrie JT; Schiff D; Fadul CE; Mrachek EK; Lopes MB; Jain R; Patel SH
AJNR Am J Neuroradiol; 2019 Mar; 40(3):426-432. PubMed ID: 30705071
[TBL] [Abstract][Full Text] [Related]
7. Histone epiproteomic profiling distinguishes oligodendroglioma, IDH-mutant and 1p/19q co-deleted from IDH-mutant astrocytoma and reveals less tri-methylation of H3K27 in oligodendrogliomas.
Feller C; Felix M; Weiss T; Herold-Mende C; Zhang F; Kockmann T; Sahm F; Aebersold R; von Deimling A; Reuss DE
Acta Neuropathol; 2020 Jan; 139(1):211-213. PubMed ID: 31773240
[No Abstract] [Full Text] [Related]
8. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
[TBL] [Abstract][Full Text] [Related]
9. Anaplastic Glioma: Treatment Approaches in the Era of Molecular Diagnostics.
Ruff MW; Uhm J
Curr Treat Options Oncol; 2018 Oct; 19(12):61. PubMed ID: 30361986
[TBL] [Abstract][Full Text] [Related]
10. Low-grade and anaplastic oligodendroglioma.
Van Den Bent MJ; Bromberg JE; Buckner J
Handb Clin Neurol; 2016; 134():361-80. PubMed ID: 26948366
[TBL] [Abstract][Full Text] [Related]
11. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.
Sahm F; Reuss D; Koelsche C; Capper D; Schittenhelm J; Heim S; Jones DT; Pfister SM; Herold-Mende C; Wick W; Mueller W; Hartmann C; Paulus W; von Deimling A
Acta Neuropathol; 2014 Oct; 128(4):551-9. PubMed ID: 25143301
[TBL] [Abstract][Full Text] [Related]
12. A review of adult-type diffuse gliomas in the WHO CNS5 classification with special reference to Astrocytoma, IDH-mutant and Oligodendroglioma, IDH-mutant and 1p/19q codeleted.
Santosh V; Rao S
Indian J Pathol Microbiol; 2022 May; 65(Supplement):S14-S23. PubMed ID: 35562130
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic Utility of Oncomine Comprehensive Assay v3 in Differentiating Between Isocitrate Dehydrogenase (IDH)-mutated Grade II-III Astrocytoma and Oligodendroglioma.
Kim SW; Park BJ; Kim HS; Na K
In Vivo; 2021; 35(2):921-927. PubMed ID: 33622884
[TBL] [Abstract][Full Text] [Related]
14. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
Anand S; Chatterjee A; Gupta T; Panda P; Moiyadi A; Epari S; Patil V; Krishnatry R; Goda JS; Jalali R
World Neurosurg; 2021 Oct; 154():e176-e184. PubMed ID: 34245877
[TBL] [Abstract][Full Text] [Related]
15. The Applicability of Haarlem Integrated Diagnostic System in Diffuse Glial Tumors and Molecular Methods Affecting Prognosis.
Kaya Terzi N; Yılmaz İ; Öz AB
Balkan Med J; 2019 Jul; 36(4):222-228. PubMed ID: 30592195
[TBL] [Abstract][Full Text] [Related]
16. The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients.
Hacisalihoglu P; Kucukodaci Z; Gundogdu G; Bilgic B
Turk Neurosurg; 2017; 27(5):682-689. PubMed ID: 27651340
[TBL] [Abstract][Full Text] [Related]
17. Clinical discussion of the management of anaplastic oligodendroglioma/oligoastrocytoma (both codeleted and nondeleted).
Anderson MD; Gilbert MR
J Natl Compr Canc Netw; 2014 May; 12(5):665-72. PubMed ID: 24812135
[TBL] [Abstract][Full Text] [Related]
18. Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true "oligoastrocytoma"?
Huse JT; Diamond EL; Wang L; Rosenblum MK
Acta Neuropathol; 2015 Jan; 129(1):151-3. PubMed ID: 25359109
[No Abstract] [Full Text] [Related]
19. Assessment of the impact of glioma diagnostic reclassification following the new 2016 WHO classification on a series of cases.
Valera-Melé M; Mateo Sierra O; Sola Vendrell E; Guzmán de Villoria L JA; Carvajal Díaz L; Gil de Sagredo Del Corral ÓL; García Leal R
Neurocirugia (Astur : Engl Ed); 2019; 30(1):19-27. PubMed ID: 30366644
[TBL] [Abstract][Full Text] [Related]
20. FISH analyses for 1p and 19q status on gliomas: Reporting an 8 years' experience from a tertiary care center in the Middle East.
Massaad E; Tabbarah A; Barmada M; Rbeiz J; Nasser S; Farra C
Ann Diagn Pathol; 2022 Apr; 57():151899. PubMed ID: 35063798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
